NCT02933814

Liposomal Bupivacaine in Ambulatory Hand Surgery

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Loma Linda University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to evaluate pain management regimens following ambulatory hand surgery. Improved pain control may be associated with decreased complications, decreased pain scores, decreased opioid dependence, improved patient comfort and satisfaction, and reduced healthcare costs. Liposomal bupivacaine is an FDA-approved local anesthetic. There will be two groups. One group will receive liposomal bupivacaine. One group will not. The results will be compared. Patients will be over the age of 18 ambulatory hand surgery. Approximately 40 subjects will participate in this study at LLU.

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	Liposomal Bupivicaine	Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.

Timeline

• Start date: 2018-02-09
• Primary completion: 2019-02-01
• Completion: 2019-02-01
• First posted: 2016-10-14
• Last updated: 2019-08-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study